Bolt Biotherapeutics (NASDAQ:BOLT) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Bolt Biotherapeutics (NASDAQ:BOLT) from a sell rating to a hold rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company’s principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California. “

Separately, SVB Leerink reduced their price target on shares of Bolt Biotherapeutics from $37.00 to $33.00 and set an outperform rating for the company in a research report on Monday, May 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $40.00.

Shares of NASDAQ:BOLT opened at $13.88 on Monday. Bolt Biotherapeutics has a fifty-two week low of $12.57 and a fifty-two week high of $43.07. The stock has a 50-day simple moving average of $16.14. The company has a current ratio of 22.58, a quick ratio of 22.58 and a debt-to-equity ratio of 0.03. The stock has a market cap of $504.37 million and a price-to-earnings ratio of -0.62.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Thursday, May 13th. The company reported ($0.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.22). As a group, sell-side analysts anticipate that Bolt Biotherapeutics will post -2.08 EPS for the current year.

Several large investors have recently made changes to their positions in the stock. Novo Holdings A S bought a new position in shares of Bolt Biotherapeutics during the 1st quarter valued at approximately $148,226,000. Vivo Capital LLC bought a new position in shares of Bolt Biotherapeutics during the 1st quarter valued at approximately $127,404,000. Citadel Advisors LLC bought a new position in shares of Bolt Biotherapeutics during the 1st quarter valued at approximately $96,209,000. RA Capital Management L.P. bought a new position in shares of Bolt Biotherapeutics during the 1st quarter valued at approximately $78,271,000. Finally, Pivotal bioVenture Partners Investment Advisor LLC bought a new position in shares of Bolt Biotherapeutics during the 1st quarter valued at approximately $62,248,000. Institutional investors own 86.68% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers.

Further Reading: What does an equal weight rating mean?

Get a free copy of the Zacks research report on Bolt Biotherapeutics (BOLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.